Categories of drug safety in pregnancy and their impact on prescribing

Classification systems

Drug safety in pregnancy classification systems vary by jurisdiction - the Australian TGA system uses categories A, B1/B2/B3, C, D, and X based on available human/animal data, while the US FDA abolished its older A/B/C/D/X letter system in 2015 in favour of a narrative Pregnancy and Lactation Labeling Rule (PLLR) format describing specific risks and available evidence rather than a single letter grade
Relevant to essentially any prescribing decision in a pregnant or potentially pregnant patient, given the need to weigh maternal treatment benefit against fetal risk for nearly every medication considered

Category assignment reflects available evidence quality and observed/theoretical risk, not necessarily actual clinical risk magnitude - a drug categorised in a "higher-risk" category may simply have less reassuring data available rather than confirmed greater harm, while a "lower-risk" category does not guarantee absolute safety, only that available evidence has not demonstrated significant risk to that point

Category should be interpreted alongside the specific clinical scenario - gestational timing (first trimester organogenesis carries different risk considerations than later pregnancy for many drugs), dose, duration, and the severity of the maternal condition being treated all modify the actual risk-benefit calculation beyond the category label alone
Specialist teratology/medicines-in-pregnancy information services can provide more nuanced, current guidance than the category system alone for complex or uncertain scenarios

Untreated maternal disease itself often carries fetal risk (e.g. poorly controlled maternal epilepsy, depression, or diabetes), meaning the correct comparison is treated vs untreated maternal condition, not treatment risk in isolation - stopping an effective, reasonably safe medication out of general pregnancy caution can sometimes cause more harm than continuing it
Category systems should inform, not replace, individualised risk-benefit discussion with the patient

US FDA PLLR system replacing the old letter categories (2015, narrative risk description), Australian TGA category system (still letter-based), untreated maternal disease risk as the necessary comparator, teratology information service consultation for complex cases

Drug safety category systems describe evidence availability and theoretical risk, not a simple safe/unsafe binary - the clinically important comparison is always treated versus untreated maternal condition, since untreated disease (epilepsy, depression, diabetes, and others) itself frequently carries meaningful fetal risk that can exceed the risk of continuing a reasonably safe medication

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.